Managing BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer (NMIBC): Clinical and Operational Perspectives : Episode 16
Opinion
Video
Navigating BCG-Unresponsive NMIBC and Emerging Therapies
Author(s):
A panelist discusses how BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC) has evolved from having limited treatment options beyond radical cystectomy to now having several therapeutic alternatives including intravesical chemotherapy and immunotherapy, though each current option comes with its own efficacy limitations and adverse effect profiles that must be carefully weighed against patient factors.
- Would you please start by giving a brief overview of BCG-unresponsive NMIBC?
- Prior to recent therapeutic innovations in the bladder space, what challenges or unmet needs did you face when treating these patients?
- Please review the standard treatment options (intravesical chemotherapy, PD-L1 inhibitors, other immunotherapeutic options) currently available for patients with BCG-unresponsive NMIBC.
- What advantages and limitations do these options have?
Related Videos
Related Content
